CD274 and non-small cell lung carcinoma: Similar results were seen in Checkmate-057 (nivolumab in non-squamous NSCLC) and Keynote-010 (pembrolizumab in advanced NSCLC) [5,32], particularly in PDL-1 > 50% patients who derived a median overall survival (OS) of 14.9 months on pembrolizumab vs. 8.2 months on docetaxel (HR 0.54, 95% CI [0.38–0.77]).